AEON Biopharma, Inc.
Business
AEON Biopharma is a biopharmaceutical company developing ABP-450, a botulinum toxin complex biosimilar to Botox® (onabotulinumtoxinA), targeting regulatory approval in the United States for therapeutic indications including chronic migraine, cervical dystonia, spasticity, and overactive bladder. The company is advancing ABP-450 through the FDA's Section 351(k) biosimilar pathway, with exclusive development and commercialization rights in the U.S., Canada, European Union, United Kingdom, and select international territories. ABP-450 is manufactured by Daewoong Pharmaceutical under cGMP-compliant processes and has been previously approved for cosmetic use in multiple countries as Jeuveau® and Nabota®.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|
| Selling, general and administrative | 12 | 14 | 14 | — | |
| Research and development | 4 | 14 | 35 | — | |
| Change in fair value of contingent consideration | −4 | −101 | — | — | |
| Total operating costs and expenses | 13 | −73 | 48 | — | |
| (Loss) income from operations | −13 | 73 | −48 | −2 | |
| Change in fair value of convertible notes | −23 | 3 | −4 | — | |
| Change in fair value of warrants | 85 | −15 | 7 | 11 | |
| Loss on issuance of warrants | −76 | — | — | — | |
| Loss on embedded forward purchase agreements | — | −20 | — | — | |
| Loss on derivative liability | −13 | — | — | — | |
| Other income, net | 290,000 | 95,000 | 289,000 | — | |
| Total other loss, net | −26 | −31 | −4 | 10 | |
| (Loss) income before taxes | −39 | 42 | −53 | 8 | |
| Income taxes | 0 | 0 | 0 | — | |
| Net (loss) income | −39 | 42 | 10 | 8 | |
| Basic net (loss) income per share (in dollars per share) | −3.95 | 77.74 | −0.38 | — | |
| Diluted net (loss) income per share (in dollars per share) | −3.95 | 72.93 | −0.38 | — | |
| Weighted average shares of common stock outstanding used to compute basic net (loss) income per share | 10 | 540,360 | 139 | — | |
| Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share | 10 | 575,945 | 139 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-07-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 13,000 | 5 | 31 | 31 | |
| Prepaid expenses and other current assets | 392,000 | 2 | 1 | — | 92,000 | |
| Total current assets | 3 | 2 | 6 | — | 10 | |
| Property and equipment, net | 162,000 | 235,000 | 332,000 | — | 431,000 | |
| Operating lease right-of-use asset | 1 | 1 | 262,000 | — | 475,000 | |
| Other assets | 948,000 | 29,000 | 29,000 | — | 34,000 | |
| Total assets | 6 | 3 | 7 | — | 11 | |
| Accounts payable | 942,000 | 6 | 3 | — | 8 | |
| Accrued clinical trials expenses | 1 | 4 | 5 | — | 2 | |
| Accrued compensation | 3 | 1 | 943,000 | — | 1 | |
| Other accrued expenses | 2 | 4 | 4 | — | 740,000 | |
| Total current liabilities | 7 | 14 | 13 | — | 83 | |
| Convertible notes at fair value, including related party amount of $34,600 and $11,689, at December 31, 2025 and 2024, respectively | 35 | 12 | — | — | 60 | |
| Operating lease liability | 893,000 | 1 | — | — | 242,000 | |
| Derivative liability | 15 | — | — | — | — | |
| Warrant liabilities | 3 | 1 | 1 | — | — | |
| Contingent consideration liability | 42,000 | 4 | 104 | — | — | |
| Total liabilities | 61 | 32 | 160 | — | 143 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at December 31, 2025 and 2024, and 12,105,902 and 555,511 shares issued and outstanding at December 31, 2025 and 2024, respectively | 9,000 | 4,000 | 4,000 | — | 14,000 | |
| Additional paid-in capital | 416 | 403 | 381 | — | 187 | |
| Accumulated deficit | −471 | −432 | −474 | — | −475 | |
| Total stockholders' deficit | −55 | −29 | −153 | −311 | −270 | |
| Total liabilities and stockholders' deficit | 6 | 3 | 7 | — | 11 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|
| Net (loss) income | −39 | 42 | −53 | 8 | |
| Depreciation | 78,000 | 97,000 | 68,000 | — | |
| Stock-based compensation expense | 5 | 6 | 6 | — | |
| Non-cash issuance of common stock | 250,000 | 384,000 | — | — | |
| Prepaid expenses and other current assets | 1 | −513,000 | −66,000 | — | |
| Accounts payable | −5 | 3 | 7 | — | |
| Accrued expenses and other liabilities | −2 | −1 | −105,000 | — | |
| Other assets and liabilities | −952,000 | 120,000 | −174,000 | — | |
| Net cash used in operating activities | −17 | −20 | −36 | −1 | |
| Purchases of property and equipment | −4,000 | — | −306,000 | — | |
| Net cash used in investing activities | −4,000 | — | −306,000 | −276 | |
| Proceeds from issuance of convertible notes | — | 15 | 45 | — | |
| Net cash provided by financing activities | 20 | 15 | 41 | 278 | |
| Net decrease in cash | 3 | −5 | 5 | 497,412 | |
| Settlement of liability with common shares | 235,000 | — | — | — | |
| Cashless warrant exercises | 7 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is AEON Biopharma, Inc.'s CIK number?
AEON Biopharma, Inc.'s SEC CIK number is 0001837607 (1837607). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find AEON Biopharma, Inc.'s SEC filings?
All of AEON Biopharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did AEON Biopharma, Inc. last report earnings?
AEON Biopharma, Inc. (AEON) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001837607-26-000041). This is AEON Biopharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is AEON Biopharma, Inc.'s most recent earnings 8-K?
AEON Biopharma, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001837607-26-000041. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View AEON Biopharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →